Kadmon Corporation, a biopharmaceutical company, offers products and services for the treatment and management of hepatitis C. Its products include Ribasphere RibaPak (ribavirin, USP) tablets, which help to reduce pill burden while providing patients with treatment that is biologically equivalent to other ribavirin medications; INFERGEN (interferon alfacon-1) to treat chronic hepatitis C in patients 18 years of age or older with compensated liver disease; Ribasphere (ribavirin, USP) tablets and capsules, which are antiviral medications for use in combination with other drugs for the treatment of chronic hepatitis C; and KD020, a reversible tyrosine kinase inhibitor that targets EGFR, HER2, VEGFR 2/3, and Src in autosomal dominant polycystic kidney disease (PKD). The company also provides various services and programs to support patients, prescribers, and pharmacies, including patient assistance programs to provide free medication to patients with limited or no insurance coverage; temporary shipments for patients on current or recent therapy; and nurse support services. In addition, it develops medicines in oncology, infectious diseases, immunology, and neurodegenerative diseases. The company was formerly known as Kadmon Holdings. Kadmon Corporation was incorporated in 2009 and is based in New York, New York with operations in Warrendale, Pennsylvania; and Boston, Massachusetts.